BR112016021985A2 - Formulação farmacêutica, método para induzir perda de peso ou redução de gordura corporal, método para melhorar a homeostase da glicose e composto - Google Patents
Formulação farmacêutica, método para induzir perda de peso ou redução de gordura corporal, método para melhorar a homeostase da glicose e compostoInfo
- Publication number
- BR112016021985A2 BR112016021985A2 BR112016021985A BR112016021985A BR112016021985A2 BR 112016021985 A2 BR112016021985 A2 BR 112016021985A2 BR 112016021985 A BR112016021985 A BR 112016021985A BR 112016021985 A BR112016021985 A BR 112016021985A BR 112016021985 A2 BR112016021985 A2 BR 112016021985A2
- Authority
- BR
- Brazil
- Prior art keywords
- homeostasis
- compound
- weight loss
- pharmaceutical formulation
- body fat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/30—Unsaturated compounds
- C07C62/38—Unsaturated compounds containing keto groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461970839P | 2014-03-26 | 2014-03-26 | |
| US61/970,839 | 2014-03-26 | ||
| PCT/US2015/022746 WO2015148802A1 (en) | 2014-03-26 | 2015-03-26 | Celastrol and derivatives for the treatment of obesity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112016021985A2 true BR112016021985A2 (pt) | 2017-08-15 |
| BR112016021985A8 BR112016021985A8 (pt) | 2021-06-29 |
| BR112016021985B1 BR112016021985B1 (pt) | 2022-08-30 |
Family
ID=52823863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016021985-6A BR112016021985B1 (pt) | 2014-03-26 | 2015-03-26 | Formulação farmacêutica |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20150274634A1 (pt) |
| EP (1) | EP3122347B1 (pt) |
| JP (1) | JP2017513824A (pt) |
| CN (2) | CN117357538A (pt) |
| AU (2) | AU2015235979B2 (pt) |
| BR (1) | BR112016021985B1 (pt) |
| CA (2) | CA3044998A1 (pt) |
| ES (1) | ES2813424T3 (pt) |
| RU (1) | RU2706239C2 (pt) |
| WO (1) | WO2015148802A1 (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9115163B2 (en) | 2007-10-19 | 2015-08-25 | The Trustees Of Columbia University In The City Of New York | DNA sequence with non-fluorescent nucleotide reversible terminators and cleavable label modified nucleotide terminators |
| US20170209408A1 (en) * | 2014-04-03 | 2017-07-27 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
| EP3364956A4 (en) * | 2015-10-23 | 2019-05-01 | ERX Pharmaceuticals, Inc. | CELASTROL ANALOGUES |
| US10053693B2 (en) | 2016-01-19 | 2018-08-21 | Mubin I. Syed | Method for controlling obesity using minimally invasive means |
| WO2017214709A1 (en) | 2016-06-15 | 2017-12-21 | NOISEUX, Nicolas | Reagents, compositions and methods for improving viability and function of cells, tissues and organs |
| US10808005B2 (en) | 2016-07-04 | 2020-10-20 | Ixmedicine (Xiamen) Biological Technology Company Limited | Ligand for orphan nuclear receptor Nur77 and uses thereof |
| CN106243181A (zh) * | 2016-07-29 | 2016-12-21 | 合肥中科玛卡生物技术有限公司 | 一种从苦瓜中提取雷公藤红素的方法 |
| US20200000752A1 (en) * | 2016-08-03 | 2020-01-02 | Vanderbilt University | Method for Treating Epilepsy |
| CN111821308B (zh) * | 2019-04-15 | 2021-10-08 | 中国科学院上海药物研究所 | 雷藤舒在制备用于治疗非酒精性脂肪性肝病的药物中的应用 |
| WO2021047672A1 (en) * | 2019-09-12 | 2021-03-18 | Ixmedicine Co., Ltd | Triterpenoid compounds, pharmaceutical compositions thereof, and their use for treating nuclear receptor subfamily 4 group member 1-mediated disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650167A (en) * | 1995-11-16 | 1997-07-22 | Dawa Incorporated | Method and composition for treating hepatitis B |
| WO2004037180A2 (en) * | 2002-10-21 | 2004-05-06 | Metaproteomics, Llc | Compositions that treat or inhibit pathological conditions associated with inflammatory response |
| US8236769B2 (en) * | 2005-09-30 | 2012-08-07 | Morinaga Milk Industry Co., Ltd. | Agent for improving insulin resistance |
| US20100240581A1 (en) * | 2006-11-13 | 2010-09-23 | The Trustees Of Columbia University In The City Of New York | Selective proteasome inhibitors for treating diabetes |
| US8641155B2 (en) * | 2007-07-26 | 2014-02-04 | David Lee | Modular furniture system |
| WO2009026163A1 (en) * | 2007-08-17 | 2009-02-26 | Burnham Institute For Medical Research | Compositions and methods for inhibiting growth and metastasis of melanoma |
| CN101434635B (zh) * | 2007-11-16 | 2012-05-16 | 上海华拓医药科技发展股份有限公司 | 一类具抗肿瘤活性的水溶性酚性三萜化合物及其制备方法 |
| WO2009100037A1 (en) * | 2008-02-01 | 2009-08-13 | The Scripps Research Institute | Methods for treating a condition characterized by dysfunction in protein homeostasis |
| JP5780549B2 (ja) * | 2009-04-17 | 2015-09-16 | 国立大学法人広島大学 | レプチン抵抗性を改善および／または予防するための薬学的組成物、並びにその使用 |
| JP2013536203A (ja) * | 2010-08-23 | 2013-09-19 | スーチョウ・ニューファーマ・カンパニー・リミテッド | 特定の化学成分、組成物および方法 |
| PL2804865T3 (pl) * | 2012-01-20 | 2016-06-30 | Idorsia Pharmaceuticals Ltd | Heterocykliczne pochodne amidowe jako antagoniści receptora p2x7 |
| CN104812898B (zh) * | 2012-05-25 | 2018-01-30 | 博格有限责任公司 | 通过调节热休克蛋白质(HSP)90‑β治疗代谢综合征的方法 |
| RS58010B1 (sr) * | 2012-09-27 | 2019-02-28 | Childrens Medical Ct Corp | Jedinjenja za lečenje gojaznosti i postupci za njihovu upotrebu |
| CN103524592B (zh) * | 2013-09-27 | 2015-08-05 | 安徽医科大学 | 一种雷公藤红素衍生物、该衍生物的生物盐及其制备方法与用途 |
-
2015
- 2015-03-26 AU AU2015235979A patent/AU2015235979B2/en active Active
- 2015-03-26 CA CA3044998A patent/CA3044998A1/en not_active Abandoned
- 2015-03-26 BR BR112016021985-6A patent/BR112016021985B1/pt active IP Right Grant
- 2015-03-26 EP EP15715606.8A patent/EP3122347B1/en active Active
- 2015-03-26 CN CN202311282376.1A patent/CN117357538A/zh active Pending
- 2015-03-26 JP JP2016558721A patent/JP2017513824A/ja active Pending
- 2015-03-26 ES ES15715606T patent/ES2813424T3/es active Active
- 2015-03-26 WO PCT/US2015/022746 patent/WO2015148802A1/en active Application Filing
- 2015-03-26 US US14/669,787 patent/US20150274634A1/en not_active Abandoned
- 2015-03-26 CN CN201580027586.3A patent/CN107073016A/zh active Pending
- 2015-03-26 RU RU2016141567A patent/RU2706239C2/ru active
- 2015-03-26 CA CA2944030A patent/CA2944030C/en active Active
-
2018
- 2018-02-21 US US15/901,401 patent/US20180194709A1/en not_active Abandoned
- 2018-10-30 US US16/175,613 patent/US20190062254A1/en not_active Abandoned
-
2019
- 2019-04-15 AU AU2019202601A patent/AU2019202601A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA3044998A1 (en) | 2015-10-01 |
| BR112016021985B1 (pt) | 2022-08-30 |
| AU2019202601A1 (en) | 2019-05-02 |
| WO2015148802A1 (en) | 2015-10-01 |
| EP3122347A1 (en) | 2017-02-01 |
| EP3122347B1 (en) | 2020-06-03 |
| JP2017513824A (ja) | 2017-06-01 |
| BR112016021985A8 (pt) | 2021-06-29 |
| US20150274634A1 (en) | 2015-10-01 |
| CN107073016A (zh) | 2017-08-18 |
| RU2016141567A3 (pt) | 2018-04-27 |
| RU2706239C2 (ru) | 2019-11-15 |
| US20190062254A1 (en) | 2019-02-28 |
| RU2016141567A (ru) | 2018-04-27 |
| CN117357538A (zh) | 2024-01-09 |
| CA2944030A1 (en) | 2015-10-01 |
| AU2015235979B2 (en) | 2019-05-02 |
| ES2813424T3 (es) | 2021-03-23 |
| AU2015235979A1 (en) | 2016-10-20 |
| US20180194709A1 (en) | 2018-07-12 |
| CA2944030C (en) | 2019-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016021985A2 (pt) | Formulação farmacêutica, método para induzir perda de peso ou redução de gordura corporal, método para melhorar a homeostase da glicose e composto | |
| HK1257781A1 (zh) | 含抗-pd-1抗體avelumab的水性藥物製劑 | |
| IL248392A0 (en) | Human antibodies to Middle East respiratory syndrome coronavirus spike protein | |
| ZA201608077B (en) | Combination, composition, and method of administering the combination or composition to animals | |
| BR112015031475A2 (pt) | composto, composição farmacêutica, método para tratamento de uma doença ou condição, kit, e, uso de composto. | |
| BR112016022062A2 (pt) | Combinação, composição farmacêutica, uso de uma combinação ou de uma composição farmacêutica, e, produto farmacêutico | |
| BR112016021034A2 (pt) | Composição farmacêutica, uso de tal composição, método para tratar uma doença e kit | |
| BR112016018085A2 (pt) | composições sinérgicas de suplemento dietético para prevenção, tratamento ou controle de doenças inflamatórias e respectivo método de aplicação das composições sinérgicas | |
| MA54716A (fr) | Réduction de la viscosité de formulations pharmaceutiques | |
| EP3196211A4 (en) | Human antibody specific to c-met and preparation method therefor | |
| UY35747A (es) | Derivados sustituidos de fenilalanina | |
| DK3199161T3 (da) | Farmaceutisk præparat | |
| BR112017027349A2 (pt) | método para melhorar os benefícios de saúde | |
| ES2956684T8 (es) | Productos para la administración de compuestos terapéuticos/de diagnóstico al corazón | |
| HK1211594A1 (en) | Human relaxin analogue, pharmaceutical composition of same, and pharmaceutical application of same | |
| BR112018002283A2 (pt) | Composição para administração tópica a um sujeito, e, formulação tópica | |
| DK3313370T3 (da) | Oftalmologisk farmaceutisk sammensætning | |
| BR112015001595A2 (pt) | composição farmacêutica, uso de um extrato torrado, e, método para intensificar um ou mais efeito (s) terapêutico (s) de xantohumol e para a produção de uma composição farmacêutica | |
| HK1220984A1 (zh) | 種硫酸酯化聚古洛糖酸多糖或其可藥用鹽及其製備方法和用途 | |
| DK3247394T3 (da) | Farmaceutisk formulering omfattende anti-egfr-antistof | |
| BR112018000201A2 (pt) | composições alimentares para gerenciamento de peso corporal | |
| DOP2015000290A (es) | Benzoxazoles sustituidos | |
| TH183269B (th) | องค์ประกอบทางยาที่ใช้กับผิวหนัง | |
| MA42111A (fr) | Compositions pharmaceutiques topiques | |
| TH1501007100A (th) | องค์ประกอบทางเภสัชกรรม, การเตรียม และการใช้ของมัน |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: THE GENERAL HOSPITAL CORPORATION (US) |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/03/2015, OBSERVADAS AS CONDICOES LEGAIS |